Eli Lilly is expected to continue seeing strong results due to tirzepatide, its key growth driver. This drugmaker is well-positioned to withstand competition in the weight loss market. Valuation should not be a major concern for investors. Over the past five years, Eli Lilly has made significant breakthroughs in the pharmaceutical sector, leading to impressive financial results and stock price growth. Despite competition in its key therapeutic area, Eli Lilly remains a top stock pick. The company’s tirzepatide has generated substantial revenue, surpassing Keytruda as the world’s best-selling medicine. Eli Lilly is also developing promising candidates like orforglipron and retatrutide, which could further solidify its position in the anti-obesity market.

Read more at Yahoo Finance: This Healthcare Stock Could Be One of the Best Companies to Own in 2026